Equities research analysts at StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Price Performance
Shares of NASDAQ:RDHL opened at $0.31 on Tuesday. The company’s 50-day moving average price is $0.55 and its two-hundred day moving average price is $1.23. RedHill Biopharma has a one year low of $0.26 and a one year high of $24.01.
RedHill Biopharma (NASDAQ:RDHL – Get Free Report) last issued its quarterly earnings results on Thursday, August 17th. The biotechnology company reported $36.00 EPS for the quarter. RedHill Biopharma had a net margin of 354.95% and a negative return on equity of 328.99%. The firm had revenue of $1.80 million for the quarter.
Institutional Investors Weigh In On RedHill Biopharma
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
- Five stocks we like better than RedHill Biopharma
- Energy and Oil Stocks Explained
- Catch the dip on Sociedad Quimica before earnings?
- Election Stocks: How Elections Affect the Stock Market
- Can new GPT store spur generative AI monetization?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Energy looks to dominate markets with 3 oil and gas stocks
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.